0001567619-22-006130.txt : 20220302
0001567619-22-006130.hdr.sgml : 20220302
20220302204012
ACCESSION NUMBER: 0001567619-22-006130
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220301
FILED AS OF DATE: 20220302
DATE AS OF CHANGE: 20220302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zhen Marianne
CENTRAL INDEX KEY: 0001750085
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 22706346
MAIL ADDRESS:
STREET 1: C/O INNOVIVA, INC.
STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
FORMER COMPANY:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
4
1
doc1.xml
FORM 4
X0306
4
2022-03-01
0
0001080014
Innoviva, Inc.
INVA
0001750085
Zhen Marianne
1350 OLD BAYSHORE HIGHWAY, SUITE 400
BURLINGAME
CA
94040
0
1
0
0
Chief Accounting Officer
Common Stock
2022-03-01
4
A
0
6691
0
A
38872
D
Non-statutory Stock Option
18.68
2022-03-01
4
A
0
15000
0
A
2023-02-20
2032-02-28
Common Stock
15000
20000
D
The Reporting Person was granted a time-based restricted stock award ("RSA"). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2023, 6.25% on May 20, 2023, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company.
The Reporting Person was granted options. Twenty-five percent of the options shall vest on February 20, 2023, 6.25% on May 20, 2023, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company.
/s/ Marianne Zhen
2022-03-02